Ligand Pharmaceuticals INC DEF 14A proxy statements

Ligand Pharmaceuticals Incorporated announced its annual meeting of stockholders will be held virtually on June 5, 2026, to elect directors, ratify auditors, and approve executive compensation and equity plan amendments.

Ligand Pharmaceuticals Incorporated files a definitive proxy statement with the SEC.

Ligand Pharmaceuticals will hold its annual stockholder meeting virtually on June 6, 2025, to vote on director elections, auditor ratification, and executive compensation.

Ligand Pharmaceuticals clarifies the rationale behind its proposed equity plan amendment, emphasizing the impact of spin-out transactions and the need to retain key talent.

Ligand Pharmaceuticals issues a supplement to its proxy statement clarifying the voting standards for the approval of the amendment and restatement of its 2002 Stock Incentive Plan at the upcoming annual meeting.

Ligand Pharmaceuticals has filed a definitive proxy statement with the Securities and Exchange Commission.

Ligand Pharmaceuticals is asking stockholders to approve an amendment and restatement of its 2002 Stock Incentive Plan to increase the share reserve and extend the term.